Sensei Biotherapeutics (NASDAQ:FTH) Coverage Initiated at Citizens Jmp

Analysts at Citizens Jmp began coverage on shares of Sensei Biotherapeutics (NASDAQ:FTH) in a report issued on Monday. The brokerage set an “outperform” rating and a $51.00 price target on the stock. Citizens Jmp’s price objective suggests a potential upside of 97.14% from the company’s previous close.

A number of other equities research analysts also recently weighed in on FTH. Citigroup initiated coverage on shares of Sensei Biotherapeutics in a research report on Friday, May 22nd. They issued a “buy” rating and a $55.00 price target for the company. Loop Capital set a $50.00 price target on Sensei Biotherapeutics in a research report on Thursday, May 28th. HC Wainwright assumed coverage on Sensei Biotherapeutics in a research note on Monday, June 22nd. They set a “buy” rating and a $60.00 price objective on the stock. Wall Street Zen cut Sensei Biotherapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Finally, Leerink Partners started coverage on Sensei Biotherapeutics in a research report on Monday, April 20th. They set an “outperform” rating and a $50.00 target price for the company. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $54.00.

Sensei Biotherapeutics Price Performance

Shares of Sensei Biotherapeutics stock opened at $25.87 on Monday. Sensei Biotherapeutics has a twelve month low of $6.32 and a twelve month high of $37.90. The stock has a market capitalization of $34.67 million, a price-to-earnings ratio of -0.18 and a beta of -0.26.

Sensei Biotherapeutics (NASDAQ:FTH) last posted its quarterly earnings data on Friday, May 15th. The company reported ($131.45) earnings per share (EPS) for the quarter. As a group, equities research analysts expect that Sensei Biotherapeutics will post -16.61 EPS for the current fiscal year.

Insider Activity

In other news, CFO Brian C. Stephenson acquired 9,391 shares of the firm’s stock in a transaction that occurred on Wednesday, June 24th. The shares were acquired at an average cost of $26.13 per share, with a total value of $245,386.83. Following the completion of the purchase, the chief financial officer directly owned 26,804 shares of the company’s stock, valued at $700,388.52. The trade was a 53.93% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Anand Kiran Parikh acquired 2,806 shares of the stock in a transaction on Monday, June 22nd. The shares were purchased at an average price of $19.76 per share, with a total value of $55,446.56. Following the completion of the transaction, the chief executive officer owned 764,234 shares of the company’s stock, valued at approximately $15,101,263.84. This represents a 0.37% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last ninety days, insiders bought 49,494 shares of company stock worth $1,188,822. 7.00% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Sensei Biotherapeutics

Large investors have recently modified their holdings of the business. Renaissance Technologies LLC increased its stake in shares of Sensei Biotherapeutics by 10.6% in the 4th quarter. Renaissance Technologies LLC now owns 11,516 shares of the company’s stock valued at $123,000 after purchasing an additional 1,100 shares during the last quarter. Bank of America Corp DE lifted its holdings in shares of Sensei Biotherapeutics by 10,692.5% in the first quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock worth $1,041,000 after acquiring an additional 32,719 shares during the last quarter. Stempoint Capital LP acquired a new stake in shares of Sensei Biotherapeutics in the 1st quarter valued at approximately $4,188,000. Finally, Vivo Capital LLC acquired a new stake in shares of Sensei Biotherapeutics in the 1st quarter valued at approximately $22,758,000. Institutional investors and hedge funds own 10.50% of the company’s stock.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.